iCAD Announces Commercial Availability of Cervical Applicator for Treatment of Gynecological Cancers at American Association of Physicists in Medicine Meeting

Researchers to present new data from multiple studies supporting use of HDR electronic brachytherapy

NASHUA, NH and ANAHEIM, CA (Booth # 1239) (July 13, 2015), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the commercial availability of a new cervical applicator for the Xoft® Axxent® Electronic Brachytherapy System®. The applicator and multi-platform controller will be showcased in the iCAD/Xoft booth (#1239) at the American Association of Physicists in Medicine (AAPM) annual meeting from July 12-16, 2015 in Anaheim, CA. Data from several studies involving use of surface HDR electronic brachytherapy is also being presented in multiple poster and oral presentations throughout the meeting.

The cervical applicator, Xoft’s first multi-channel applicator, is used to deliver a precise dose of radiation to larger target areas of the cervix while minimizing exposure to healthy tissue. The addition of the cervical applicator completes Xoft’s gynecological product line, allowing radiation oncologists to treat all gynecological indications with the Xoft System.

“Cancer of the cervix continues to pose a serious health risk to a large population of women worldwide. The launch of this new applicator demonstrates iCAD’s ongoing commitment to furthering the development of HDR electronic brachytherapy technology for the treatment of gynecological cancers,” said Ken Ferry, CEO of iCAD.

Researchers are presenting new data supporting the Xoft technology in the following oral presentations at AAPM:

An Investigation of Well-Chamber Responses for An Electronic Brachytherapy Source
Wesley Culberson, PhD, DABR, University of Wisconsin
Sunday, July 12, from 4:00 p.m. to 6:00 p.m. in Ballroom A
New Efficient Method for Xoft Axxent Electronic Brachytherapy Source Calibration by Pre-Characterizing Surface Applicator
Sujatha Pai, MD, MS, DABMP
Sunday, July 12, from 4:00 p.m. to 6:00 p.m. in Ballroom A
An Innovative Solution for Data Aggregation and Collection to Improve Quality of Peer Review Using a Cloud Based Platform Within a Large Oncology Network
Jeffrey Limmer, M Ed, MSc, US Oncology
Monday, July 13, from 1:45 p.m. to 2:45 p.m. in Room 213
Determination and Evaluation of a Dose-Rate Conversion Coefficient for the Xoft Axxent® Electronic Brachytherapy Source in the Xoft Titanium Cervical Applicator
Samantha Simiele, University of Wisconsin
Thursday, July 16, from 7:30 a.m. to 9:30 a.m. in Ballroom A

Researchers also presented new data supporting the technology in the following poster presentations on Sunday, July 12 at AAPM:

Electronic Brachytherapy: A Physics Perspective On Field Implementation
Sujatha Pai, MD, MS, DABMP
Characterization of the New Xoft Axxent Electronic Brachytherapy Source Using PRESAGE Dosimeters
Angela Steinmann, MS, UT MD Anderson Cancer Center
Dosimetric Impact Due to FlexiShield in Electronic Brachytherapy (eBx) of Breast IORT: A Phantom Study
Yongbok Kim, PhD, University of Arizona Cancer Center
Evaluation of Effective Treatment Depth in Skin Cancer Treatments with Xoft Electronic Brachytherapy
Irena Dragojevic, PhD, University of California San Diego
Evaluation of Electronic Brachytherapy Dose Distributions in Tissue Equivalent Materials
Mark Johnson, MD, University of Oklahoma Health Sciences Center
Failure Mode and Effects Analysis (FMEA) of Xoft Electronic Brachytherapy for the Treatment of Superficial Skin Cancers
Jeremy Hoisak, PhD, University of California San Diego
Impact of the Radiochromic Film Energy Response On Dose Measurements of Low Energy Electronic Brachytherapy Sources
Liheng Liang, Jewish General Hospital, Medical Physics Unit, McGill University
Modeling of Breast IORT Using the Xoft 50 KV Brachytherapy Source and 316L Steel Rigid Shield
William Burnside, Mountain View, CA
Monte Carlo Calculation of Correction Factors for a Free-Air Ionization Chamber in Support of a National Air-Kerma Standard for Electronic Brachytherapy
Matthew Mille, PhD, National Institute of Standards and Technology
Multi-Helix Rotating Shield Brachytherapy for Cervical Cancer
Hossein Dadkhah, MS, University of Iowa
The Resources and Cost to Operate An Intraoperative Radiation Therapy Program for Accelerated Partial Breast Irradiation Using a Low-Energy X-Ray Source
Manuel Morales-Paliza, PhD, Vanderbilt University

“These clinical data presentations highlight the safety and efficacy of the Xoft electronic brachytherapy source as a treatment option for skin, breast and gynecological cancers. The results of these studies further confirm the clinical value of our technology across multiple applications,” Mr. Ferry added.

The Xoft System

The Xoft System is FDA cleared to treat cancer anywhere in the body, including skin, vaginal, endometrial, cervical, and early-stage breast cancer. It has been used to treat more than 10,000 patients to date across all clinical applications.

About Xoft Axxent Electronic Brachytherapy System

The Xoft System is an isotope-free radiation treatment cleared by the U.S. Food and Drug Administration and CE marked in the EU for use anywhere in the body, including for the treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. It utilizes a proprietary miniaturized x-ray as the radiation source that delivers precise treatment directly to cancerous areas while sparing healthy tissue and organs. The Xoft System requires only minimal shielding and therefore does not require room redesign or construction investment. Minimal shielding also allows medical personnel to remain in the room with the patient during treatment. The mobility of the Xoft System makes it easy to treat patients at multiple locations and to easily store the system when not in use. Xoft is a wholly owned subsidiary of iCAD, Inc. For more information about Xoft visit www.xoftinc.com, like us on Facebook or follow us on Twitter at @xofticad.

About iCAD, Inc.

iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD’s Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit or www.icadmed.com or www.xoftinc.com.

“Safe Harbor” Statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company’s ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “will”, “continue”, “anticipate”, “likely”, “seek”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at https://www.icadmed.com and on the SEC’s website at http://www.sec.gov.

Contact:

For iCAD investor relations:

The Ruth Group
Zack Kubow, 646-536-7030 /7024
iCAD@theruthgroup.com

For iCAD media inquiries:

Berry & Company Public Relations, LLC
Jessica Burns, 212-253-8881
jburns@berrypr.com